Clinical Trials Logo

Transplant Glomerulopathy clinical trials

View clinical trials related to Transplant Glomerulopathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03380962 Active, not recruiting - Clinical trials for Kidney Failure, Chronic

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Start date: February 27, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Patients who have had a previous allograft failure represent a major problem for transplant centers as they are highly-human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant desensitization. This single center, phase I/II, open label single-arm exploratory study focuses on enrolling twenty patients (ages 15-75) who will begin desensitization therapy to achieve HLA incompatible (HLAi) renal transplantation. Patients who qualify will receive up to 6 doses of clazakizumab 25 mg monthly pre-transplantation. If patients receive an HLAi transplant during the study, the participants will continue to receive another 6 monthly doses of clazakizumab 25 mg, followed by a 6 month protocol biopsy. Patients will continue another 6 doses over 6 months if improvements are seen after the 6th dose of clazakizumab. Patients who develop evidence of persistent allograft dysfunction may have non-protocol biopsies for cause. Patients who receive 12 doses of clazakizumab post-transplant will receive a 12M protocol biopsy.